{"name": "Portola Pharmaceuticals",
 "permalink": "portola-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/portola-pharmaceuticals",
 "homepage_url": "http://www.portola.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@portola.com",
 "phone_number": "650.246.7000",
 "description": "",
 "created_at": "Sat Oct 29 04:34:47 UTC 2011",
 "updated_at": "Fri May 24 05:59:25 UTC 2013",
 "overview": "\u003Cp\u003EPortola Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics for acute and chronic cardiovascular and autoimmune/inflammatory diseases. The company\u00e2\u20ac\u2122s products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery; for stroke prevention in patients with atrial fibrillation; and for secondary prevention of myocardial infarction and stroke. Its products also include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company\u00e2\u20ac\u2122s products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin\u0026#8217;s lymphoma and chronic lymphocytic leukemia. Portola Pharmaceuticals, Inc. was founded in 2003 and is based in South San Francisco, California.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       52],
      "assets/images/resized/0016/0000/160000v1-max-150x150.jpg"],
     [[232,
       81],
      "assets/images/resized/0016/0000/160000v1-max-250x250.jpg"],
     [[232,
       81],
      "assets/images/resized/0016/0000/160000v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "William",
      "last_name": "Lis",
      "permalink": "william-lis",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Mardi",
      "last_name": "C. Dier",
      "permalink": "mardi-c-dier",
      "image": null}},
   {"is_past": false,
    "title": "Executive Vice President, Research and Development",
    "person":
     {"first_name": "JOHN",
      "last_name": "T. CURNUTTE",
      "permalink": "john-t-curnutte",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$89M",
 "funding_rounds":
  [{"round_code": "d",
    "source_url": "http://www.portola.com/pdfs/Portola_Pharmaceuticals_Announces_Completion_of_89_Million_Financing.pdf",
    "source_description": "Portola Pharmaceuticals Announces Completion of $89 Million Financing",
    "raised_amount": 89000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 11,
    "funded_day": 21,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Temasek",
         "permalink": "temasek",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0009/6020/96020v3-max-150x150.png"],
             [[164,
               23],
              "assets/images/resized/0009/6020/96020v3-max-250x250.png"],
             [[164,
               23],
              "assets/images/resized/0009/6020/96020v3-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Eastern Capital",
         "permalink": "eastern-capital",
         "image":
          {"available_sizes":
            [[[150,
               37],
              "assets/images/resized/0026/1306/261306v1-max-150x150.png"],
             [[250,
               62],
              "assets/images/resized/0026/1306/261306v1-max-250x250.png"],
             [[317,
               79],
              "assets/images/resized/0026/1306/261306v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "270 E. Grand Avenue",
    "address2": "",
    "zip_code": "94080 ",
    "city": "South San Francisco",
    "state_code": "CA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": 2013,
   "pub_month": 5,
   "pub_day": 7,
   "stock_symbol": "NASDAQ:PTLA"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}